Understand payer requirements and the role of key evidence types in estimating gene therapy durability in payer assessments

Wonderful tool: dynamic and intuitive. So much useful content to be leveraged by our teams
Commercial Lead

Client Challenge

Long-term duration of effect (durability) is central to the value proposition for gene therapies. With payers gaining more experience in the evaluation of gene therapies, our client wanted to understand how payers from global markets are likely to evaluate durability, and how to optimise payer perceptions of durability for their product.

P4A Solution

Several evidence packages relevant to durability of effect were explored with payer experts.

After hypothesising expected payer perceptions, P4A validated and expended on these hypotheses and developed strategic advice to support the PRMA potential of the gene therapy.

The Successful Outcome​

We recommended evidence packages that are likely to aid the demonstration of durability in scope markets.

Payer expectations of durability for the gene therapy were evaluated, supporting our clients’ preparation for payer assessments

Need more details?

Do you want to learn more about the successful outcome for this case study? Are you interested in P4A Services or just want to say Hi?

Explore other case studies

P4A Services

For all access and Rare Disease related overview enquiries